TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
Advanced Science · 2026
DOI: 10.1002/advs.202512978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xinyu Peng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, P. R. China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Immunotherapy, Gene Editing, Doxorubicin. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jilin Province, Science and Technology Project of Jilin Provincial Education Science Department.
Abstract (Originalsprache)
Pancreatic cancer, recognized for its high malignancy and tumor immunosuppressive microenvironment, has been refractory to conventional therapeutic modalities, necessitating the exploration of novel treatment strategies. Among these, reprogramming of the tumor immunosuppressive microenvironment is a promising strategy to enhance the efficacy of tumor immunotherapy. The CRISPR/Cas9 system‐based gene editing further offers a viable approach for precise regulation of endogenous gene expression associated with tumor immunosuppression. Current delivery vectors face a trilemma between biosafety profiles, expansion capacity, and targeting accuracy. To this end, we developed a triple‐modality therapeutic platform, termed TriCON (Triple Convergent Oncology Nanotherapy), characterized by three core mechanistic attributes: spatiotemporal convergence, stimuli‐responsive controllability, and tumor‐microenvironment modulatory conductivity. This orchestrated combination of rationally designed gene editing (targeting poliovirus receptor), nano‐encapsulated doxorubicin (DOX) chemotherapy, and checkpoint blockade immunotherapy demonstrated enhanced synergistic antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models, achieving tumor regression through enhanced chemotherapy, immunogenic cell death induction, and natural killer (NK) cells activation. The platform achieved superior in vivo gene editing (14.2% PVR editing efficiency) via optimized endosomal escape and CRISPR system release. This triaxial approach establishes a programmable nanotherapeutic paradigm that synergizes gene editing precision with chemo‐immunotherapy, offering a novel framework for PDAC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, P. R. China.
- State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun, P. R. China.
- Key Laboratory of Jilin Province For Zoonosis Prevention and Control, Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, P. R. China.
- State Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, P. R. China.
- State Key Laboratory of Advanced Technology For Materials Synthesis and Processing, Wuhan University of Technology, Wuhan, P. R. China.
- Laboratory of Inorganic Materials Chemistry (CMI), University of Namur, Namur, Belgium.
ORCID-Profile: Xinyu Peng, Zhen-An Qiao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jilin Province
- Science and Technology Project of Jilin Provincial Education Science Department
- Health and Innovation Technology Project of Jilin Province
- 2025 Doctoral Research Innovation Enhancement Project of Jilin Province
Zitieren
APA
Peng, X., Huang, J., Lv, S., Zhang, J., Zhang, L., Liu, H., Liu, Y., Qiao, Z. A., Wei, F., & Su, B. L. (2026). TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202512978
Vancouver
Peng X, Huang J, Lv S, Zhang J, Zhang L, Liu H, et al. TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy. Advanced Science. 2026. doi:10.1002/advs.202512978
BibTeX
@article{Peng2026,
author = {Peng, Xinyu and Huang, Jiaxing and Lv, Shengnan and Zhang, Jian and Zhang, Liangliang and Liu, Huan and Liu, Yan and Qiao, Zhen-An and Wei, Feng and Su, Bao-Lian},
title = {TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202512978}
}
EUVIMED